Comprehensive Analysis of Ovarian Serous Borderline Tumors: Lymph Node Involvement and Implants - A Case Report Ovarian serous borderline tumors

Main Article Content

Ahmet Midi
Beste Hazneci
Yılmaz Güzel
Ayşe Nimet Karadayı


Objective: Ovarian serous borderline tumors (SBTs) are a distinct subtype of ovarian tumors that exhibit characteristics intermediate between benign tumors and invasive ovarian cancers. These tumors may display cellular changes suggestive of malignancy but do not meet all the criteria for full malignancy.

Case: This article presents the case of a 55-year-old female who presented to the clinic with complaints of pain and swelling in the lower abdominal quadrant. Upon examination, multiloculated mass lesions were found in the bilateral adnexa, and the patient was diagnosed with Borderline (low malignant potential) serous tumor. The patient underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy, partial omentectomy, and peritoneal implant excision. Additionally, pelvic lymph node resection was performed, and abdominal lavage fluid was collected. The tissue sections were examined under a light microscope, revealing epithelial-lined papillae with a complex structure resembling the columnar fallopian tube epithelium, showing hierarchical branching. The patient was diagnosed with Borderline (low malignant potential) serous tumor, omental implants, and lymph node involvement.

Conclusion: The presence of lymph node involvement and implants in ovarian SBT necessitates thorough surgical exploration and may impact the choice of therapies. Therefore, early detection and accurate staging are crucial in determining prognosis and treatment strategy.


Download data is not yet available.

Article Details

How to Cite
Midi, A., Hazneci, B. ., Güzel, Y., & Karadayı, A. N. (2024). Comprehensive Analysis of Ovarian Serous Borderline Tumors: Lymph Node Involvement and Implants - A Case Report: Ovarian serous borderline tumors. Medical Science and Discovery, 11(4), 138–142.
Case Reports
Received 2023-12-26
Accepted 2024-02-23
Published 2024-04-30


Kurman RJ, Carcangiu ML, Herrington CS, Young RHE (eds) (2014) WHO classification of tumors of female reproductive organs. Lyon, IARC.

Wetterwald L, Sarivalasis A, Liapi A, Mathevet P, Achtari C. Lymph Node Involvement in Recurrent Serous Borderline Ovarian Tumors: Current Evidence, Controversies, and a Review of the Literature. Cancers (Basel). 2023 Jan 31; 15(3):890.

Hauptmann S, Friedrich K, Redline R, Avril S. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch. 2017 Feb; 470(2):125-142.

Bell DA, Longacre TA, Prat J, Kohn EC, Soslow RA, Ellenson LH, et al. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol. 2004 Aug; 35(8):934-48.

Höhn AK, Brambs CE, Hiller GGR, May D, Schmoeckel E, Horn LC. 2020 WHO Classification of Female Genital Tumors. Geburtshilfe Frauenheilkd. 2021 Oct;81(10):1145-1153.

Sharma A, Lastra RR. Serous borderline tumor. website. Accessed September 5th, 2023

Martin M, Grisham RN, Turashvili G, Halpenny DF, Aghajanian CA, Makker V. Brain metastasis in advanced serous borderline tumor of the ovary: A case presentation. Gynecol Oncol Rep. 2017 Sep 6; 22:9-12.

Malham MB, Mehawej J, Filippaios A, Kushnir C, Mhawech-Fauceglia P. Bilateral Ovarian Serous Borderline Tumor with Non-Invasive Endometrial Implants. Case Rep Obstet Gynecol. 2023 June 8; 2023:4845887.

Hannibal CG, Vang R, Junge J, Frederiksen K, Kjærbye-Thygesen A, Andersen KK, et al. A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population. Gynecol Oncol. 2014 Aug; 134(2):267-73.

du Bois A, Trillsch F, Mahner S, Heitz F, Harter P. Management of borderline ovarian tumors. Ann Oncol. 2016 Apr; 27 Suppl 1:i20-i22

Trope C, Kaern J, Vergote IB, Kristensen G, Abeler V. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol. 1993; 51(2):236–243

Minagawa M, Maeda M, Shimauchi M, Kishi H, Teshima S. Serous borderline tumor with micropapillary pattern of the right ovary that developed 6 recurrences over 30 years after primary surgery. Gynecol Oncol Rep. 2018 May 31; 25:45-47.

Maniar KP, Wang Y, Visvanathan K, Shih Ie M, Kurman RJ. Evaluation of microinvasion and lymph node involvement in ovarian serous borderline/atypical proliferative serous tumors: a morphologic and immunohistochemical analysis of 37 cases. Am J Surg Pathol. 2014; 38(6):743–755.

Sobin LH, Compton CC. TNM seventh edition: what's new, what's changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer. 2010 Nov 15; 116(22):5336-9.

McKenney JK, Balzer BL, Longacre TA. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification. Am J Surg Pathol. 2006 May;30(5):614-24.

Longacre TA. Benign and Low Grade Serous Epithelial Tumors: Recent Developments and Diagnostic Problems. Surg Pathol Clin. 2011 Mar;4(1):331-73.

Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000 Aug; 70(2):209-62

Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. J Clin Oncol. 2007 Jul 10; 25(20):2928-37.